Skip to content

Dyskeratosis Congenita Autosomal Dominant 4 C3808802

Published: July 22, 2026Updated: August 20, 2026

An autosomal dominant form of dyskeratosis congenita with similar features to other types. It causes skin, nail, and mucosal changes with increased cancer risk. Lifelong monitoring and supportive care are essential.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Hematopoietic stem cell transplantation

Definitive treatment for bone marrow failure through replacement of affected hematopoietic cells with healthy donor stem cells, addressing the fundamental telomere biology defect in this autosomal dominant form.

surgical
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Danazol for cytopenias

Synthetic androgen therapy to stimulate hematopoietic stem cell activity and improve peripheral blood counts in bone marrow failure when transplantation is not immediately feasible.

medication

Additional treatment options

Pulmonary function monitoring

Serial pulmonary function testing and imaging to detect interstitial lung disease and pulmonary fibrosis, major causes of morbidity in dyskeratosis congenita type AD4.

monitoring

Infection prevention protocols

Implementation of hygiene measures, prompt fever evaluation, prophylactic antibiotics when indicated, and avoidance strategies to minimize infection risk from immunocompromised state.

lifestyle

Stress management and wellness support

Integrative approaches including meditation, gentle exercise, and stress reduction techniques to support overall wellbeing and potentially modulate inflammatory pathways.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dyskeratosis Congenita Autosomal Dominant 4 C3808802?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dyskeratosis Congenita Autosomal Dominant 4 C3808802. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy